Integrated BioPharma, Inc. (OTCMKTS:INBP – Get Rating) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,800 shares, a growth of 1,700.0% from the March 31st total of 100 shares. Based on an average trading volume of 19,000 shares, the short-interest ratio is currently 0.1 days.
INBP traded down $0.09 on Wednesday, reaching $0.72. The company had a trading volume of 71,674 shares, compared to its average volume of 14,095. The company has a fifty day moving average of $0.84 and a 200-day moving average of $0.96. The company has a market capitalization of $21.51 million, a P/E ratio of 3.13 and a beta of 0.27. Integrated BioPharma has a one year low of $0.27 and a one year high of $1.25.
Integrated BioPharma (OTCMKTS:INBP – Get Rating) last announced its earnings results on Thursday, February 10th. The company reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $14.59 million during the quarter. Integrated BioPharma had a net margin of 11.87% and a return on equity of 53.01%.
Integrated BioPharma, Inc, together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments.
- Get a free copy of the StockNews.com research report on Integrated BioPharma (INBP)
- Xerox Holdings Stock is a Value Play
- Carl Icahn Buys More Xerox
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
Receive News & Ratings for Integrated BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.